Predicine’s Liquid Biopsy Next-Generation Sequencing (NGS) Assay is Granted Breakthrough Device Designation by U.S. Food and Drug Administration   SILICON VALLEY, Calif., (September 20, 2022) – Predicine, Inc., a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough...